{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:04:01Z","timestamp":1785683041900,"version":"3.56.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","award":["01GM1911B"],"award-info":[{"award-number":["01GM1911B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.beha.2024.101552","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T22:33:38Z","timestamp":1712183618000},"page":"101552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cytogenetics and genomics in CML and other myeloproliferative neoplasms"],"prefix":"10.1016","volume":"37","author":[{"given":"Hans H.","family":"Kreipe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Schlegelberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2024.101552_bib1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Longterm outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2024.101552_bib2","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/s41375-020-01039-7","article-title":"SAKK and the German CML Study Group. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 2020; 34: 2074-2086","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101552_bib3","first-page":"1197","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.beha.2024.101552_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staininger","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.beha.2024.101552_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.beha.2024.101552_bib6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph' translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.beha.2024.101552_bib7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.beha.2024.101552_bib8","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101552_bib9","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3390\/cancers14071712","article-title":"The cytogenetic landscape of pediatric chronic myeloid leukemia diagnosed in chronic phase","volume":"14","author":"Karow","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.beha.2024.101552_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/gcc.1112","article-title":"Integration of amplified BCR\/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression inchronic myeloid leukemia","volume":"31","author":"Metzke-Heidemann","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.beha.2024.101552_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.beha.2024.101552_bib12","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101552_bib13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2024.101552_bib14","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Sch\u00f6nfeld","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101552_bib15","first-page":"942","article-title":"Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia","volume":"109","author":"Behrens","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2024.101552_bib16","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101552_bib17","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101552_bib18","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.beha.2024.101552_bib19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2024.101552_bib20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2018.208801","article-title":"Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia","volume":"104","author":"Bidet","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2024.101552_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2024.101552_bib22","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101552_bib23","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"SAKK and the German CML Study Group. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2024.101552_bib24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428190400013068","article-title":"Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia","volume":"46","author":"Bacher","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2024.101552_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cancergen.2021.02.007","article-title":"BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone","volume":"254\u2013255","author":"Behrens","year":"2021","journal-title":"Cancer Genet"},{"key":"10.1016\/j.beha.2024.101552_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1365-2141.1997.4203237.x","article-title":"New insights into the biology of Philadelphia-chromosome-positive acutelymphoblastic leukaemia using a combination of May-Gr\u00fcnwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level","volume":"99","author":"Haferlach","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2024.101552_bib27","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/hematology.2023000447","article-title":"Resistance mutations in CML and how we approach them","volume":"2023","author":"Soverini","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2024.101552_bib28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101552_bib29","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101552_bib30","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101552_bib31","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1038\/s41467-023-41167-z","article-title":"Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.beha.2024.101552_bib32","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101552_bib33","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101552_bib34","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/ajh.27007","article-title":"Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: a work in progress","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2024.101552_bib35","article-title":"CML and the WHO: why?","author":"Berman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2024.101552_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100397","article-title":"Fifth edition of the world health classification of tumors of the hematopoietic and lymphoid tissue: myeloid neoplasms","volume":"37","author":"Loghavi","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.beha.2024.101552_bib37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hon.2430","article-title":"Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: the impact of mutation burden and histology","volume":"36","author":"Latagliata","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2024.101552_bib38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0950-3536(98)80041-3","article-title":"Molecular genetics and cytogenetics of myeloproliferative disorders","volume":"11","author":"Bench","year":"1998","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.beha.2024.101552_bib39","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101552_bib40","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2024.101552_bib41","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"MPD Research Consortium. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101552_bib42","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1038\/bcj.2011.39","article-title":"Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms","volume":"1","author":"Rice","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2024.101552_bib43","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2024.101552_bib44","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2009-08-236448","article-title":"The JAK2 46\/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms","volume":"115","author":"Jones","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101552_bib45","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/bloodadvances.2021004811","article-title":"Germline variants in DNA repair genes, including BRCA1\/2, may cause familial myeloproliferative neoplasms","volume":"5","author":"Elbracht","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2024.101552_bib46","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2024.101552_bib47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2024.101552_bib48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 updateon diagnosis, risk-stratification, and management","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2024.101552_bib49","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in poly cythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2024.101552_bib50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.leukres.2017.06.004","article-title":"Primary myelofibrosis: older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease","volume":"60","author":"Barosi","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2024.101552_bib51","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.7754\/Clin.Lab.2016.151208","article-title":"Study on the clinical significance of JAK2V617F allele burden in Philadelphia chromosome-negative myeloproliferative neoplasm","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Lab"},{"key":"10.1016\/j.beha.2024.101552_bib52","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/leu.2017.298","article-title":"Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2","volume":"32","author":"Bartels","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101552_bib53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2024.101552_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2021.09.001","article-title":"Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): a continuum of different disease entities","volume":"365","author":"Coltro","year":"2021","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.beha.2024.101552_bib55","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41375-019-0668-5","article-title":"Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis","volume":"34","author":"Bartels","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101552_bib56","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ejh.13579","article-title":"Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression","volume":"106","author":"Bartels","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2024.101552_bib57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-018-0109-0","article-title":"Myelofibrosis treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2024.101552_bib58","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2011.047811","article-title":"European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis","volume":"97","author":"Buhr","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2024.101552_bib59","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.25688","article-title":"Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management","volume":"95","author":"Szuber","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2024.101552_bib60","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/blood.2019003206","article-title":"Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia","volume":"134","author":"Duployez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101552_bib61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cancergen.2023.01.002","article-title":"Rare and potentially fatal - cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid\/lymphoid neoplasms with eosinophilia in children","volume":"272\u2013273","author":"Berking","year":"2023","journal-title":"Cancer Genet"},{"key":"10.1016\/j.beha.2024.101552_bib62","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101552_bib63","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3324\/haematol.2009.010355","article-title":"Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1","volume":"95","author":"Steinemann","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2024.101552_bib64","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ng.641","article-title":"Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia","volume":"42","author":"Niemeyer","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2024.101552_bib65","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile myelomonocytic leukemia: who's the driver at the wheel?","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101552_bib66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2011.08817.x","article-title":"Constitutional trisomy 8p11.21-q11.21 mosaicism: a germline alteration predisposing to myeloid leukaemia","volume":"155","author":"Ripperger","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692624000173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692624000173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T19:40:05Z","timestamp":1729366805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692624000173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1521692624000173"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2024.101552","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytogenetics and genomics in CML and other myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2024.101552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Hannover Medical School. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101552"}}